


9th World Conference



TARGETING Phage Therapy

JUNE 9 · 10 2026
VALENCIA · SPAIN



PROGRAM

PHAGE
THERAPY
2026

9th World Congress Targeting Phage Therapy 2026

June 9 - 10, 2026 – Valencia, Spain

Day 1 - June 9, 2026

8h00 Welcoming of attendees & Badge Distribution

8h50 Opening Remarks by Sandra Sevilla, President, CECAV, Spain & Marvin Edeas, Founder of Phage Therapy

9h00 **Keynote Speech**



Turning Evolution into Therapy: A New Strategy to Fight Antibiotic-Resistant Infections
Benjamin K. Chan, Yale University, USA

Session 1 – Advances in Phage Therapy: From Mechanisms to Clinical Translation

Chairs: Marvin Edeas, Sandra Sevilla



9h45 **Advancing Phage Therapy for Chronic Infections:
From Experimental Evidence to Clinical Use**
Joana Azeredo, University of Minho, Portugal



10h15 **Bacteriophages Redesigned: Engineering of Next-Generation
Phage Therapeutics and Diagnostics**
Martin J. Loessner, ETH Zürich, Switzerland

10h45 Coffee Break, Networking and Poster Sessions



11h30 **Shaping Phage Susceptibility Landscapes for Personalized Therapy**
Katrine Whiteson, UC Irvine, USA (Online)

12h00 Short Oral presentations

Phage–antibiotic synergy re-sensitizes MDR Klebsiella biofilms and suppresses resistance
Tinatini Tchatchiashvili, Jena University Hospital, Germany

12h10 Discussion

12h30 Lunch Break, Networking, Group Photo

PHAGE
THERAPY 2026

Session 2 – Phages Across One Health: Animal, Food, and Industry

Chairs: Pilar Garcia, Pablo Catalá Gregori



14h00 **Phage for Sustainable and Scalable Infection Control in Aquaculture**
Adelaide Almeida, Universidade de Aveiro, Portugal



14h30 **Phage Therapy in Livestock Disease Models: Lessons for Animal and Human Health**
Robert Atterbury, University of Nottingham, United Kingdom



15h00 **Nasopharyngeal Phages: The Silent Players in Piglet Health**
Oscar Mencía-Ares, Universidad de León, Spain

15h30 Coffee Break, Networking, Poster Presentation

16h15 Short Oral presentations (10 Minutes)

Chairs: Annika Y. Classen, Danish J. Malik

Investigating Phage-Antibiotic Synergy Against Multidrug-Resistant Infections
Emma Kane, Yale University, USA

Genomic indicators of bacteriophage susceptibility in ESBL-producing uropathogenic E. coli
Debra Satie Nagano, Kyorin University, Japan

Intravenous versus intravenous and inhaled delivery of bacteriophages: Pharmacokinetics and pharmacodynamics in pigs with or without ventilator-associated pneumonia
Viviane Oliveira, CIBER, Spain

Nucleotide Derivatives Activate Abortive Infection During Bacterial Antiphage Defense
Giedrius Sasnauskas, Vilnius University, Lithuania

In Vitro Assessment of Lytic Bacteriophage Specificity toward Pathogens and Probiotic Bacteria
Nicola Mangieri, University of Milan, Italy

Inhibition of a Bacterial Antiviral System by Chemical Compounds
Dziugas Sabonis, Vilnius University, Lithuania

17h15 Poster Flash Session (3 Minutes)

Large-Scale Mutagenesis of the T7 RBP Enables Infection of Otherwise Resistant Escherichia Coli Hosts
Constantinos Patinios, VU LSC-EMBL Partnership Institute, Lithuania

A Comprehensive Analysis of the Kinetics of Infection of Lytic Bacteriophages Specific to the Escape and Critical Pathogens

Olaf Bajrak, Hirszfeld's Institute of Immunology and Experimental Therapy, Poland

Formulation, Characterization, and Biofilm Eradication Efficacy of Liposome-Encapsulated Bacteriophages Against Salmonella

Manana Loladze, Eliava institute of Bacteriophages, Georgia

Modeling Pseudomonas aeruginosa biofilm and phage therapy in a cystic fibrosis ex vivo pig lung model

Marco Cafora, University of Milan, Italy

One Health Phage Library-CSIC

Pilar García, CSIC, Spain

Pseudomonas Aeruginosa Dev Phage Exploits the Essential Lptd Outer Membrane Protein as Receptor for Adsorption

Jimena Nieto, University of Milan, Italy

Synergistic Antibacterial and Antibiofilm Effect of Bacteriophage K14 in Combination with Antibiotics against Klebsiella pneumoniae

Damla Damar Celik, Marmara University, Turkey

Isolation And Characterization of Bacteriophages Against Multidrug-Resistant Enterococcus Faecalis from Poultry

Josep García-Llorens, CECAV, Spain

Phage-Based Control of Salmonella Infantis in Poultry Systems

Jan Torres-Boncompte, CECAV, Spain

17h45 End of Conference Day One

20h30 Speakers' Dinner (Reserved for ticket holders) – Register on the website

Day 2 - June 10, 2026

8h55 Welcoming of attendees

Session 3 – Production, Regulation, and Market Access

Chairs: Benjamin K. Chan, Joana Azeredo



9h00 **Personalized Bacteriophage Therapy in Germany and Beyond – A Consensus-Based Guideline**
Annika Y. Classen, Cologne University Hospital, Germany



9h30 **France launches its first public GMP Platform to produce large batches of Therapeutic Phages at affordable scale**
Frédéric Laurent, Hospices Civils de Lyon, France

10h00 Discussion

10h10 Short Oral presentations (10 Minutes)

Modular Platform for Efficient Phage Purification
Isabel Marie Nowak, Technische Hochschule Mittelhessen, Germany

The EU legal framework for one-size-fits-all versus personalized phage therapy
Timo Faltus, Martin-Luther-University Halle-Wittenberg, Germany

10h30 Coffee Break, Networking and Poster Sessions



11h15 **The Qualified Presumption of Safety (QPS) Qualification of Lytic Bacteriophages: Scientific Criteria and Regulatory Perspectives**
Juan Evaristo Suárez, Universidad de Oviedo, Spain



11h45 **From Bioreactor to Patient: Scalable Manufacturing and Delivery of Therapeutic Phages**
Danish J. Malik, Loughborough University, United Kingdom

12h15 Poster Flash Session (3 Minutes)

Engineering Safer Bacterial Hosts For Gmp Production Of Therapeutic Bacteriophages
Martin Benesik, Masaryk University/MB Pharma, Czech Republic

Clinical Development of Duofag® for Complicated Wound Infections
Dana Kocourková, MB Pharma s.r.o., Czech Republic

What the Phage 2.0: A Platform for Pre-Clinical Phage Characterization
Mike Marquet, University Hospital Jena, Germany

Isolation and Characterization of Lytic Bacteriophages Targeting Clinical Multidrug-Resistant Staphylococcus spp. as Therapeutic Candidates
María Ángeles Tormo Mas, Fundación para la Investigación del Hospital La Fe, Spain

Crono-Safe: A Targeted Thermostable Bacteriophage Cocktail Against Cronobacter Spp. With Translational Phage Therapy Potential
Michal Kajsik, Comenius University Science Park, Slovak Republic

Development of Phage Endolysin-Integrated PH-Responsive Antiadhesive and Antibacterial Coatings with Nanorods for Prevention of Cross-Contamination in Fresh Produce

Hui Shi, Southwest University, China

Structure of the LE3 Phage Infecting *Leptospira Biflexa*

Hana Šimečková, CEITEC Masaryk University, Czech Republic

Successful Phage Therapy of a *Pseudomonas Aeruginosa*-Induced Bilateral Otitis Media

Miriam Waizer, University Hospital Regensburg, Germany

Operationalizing Clinical Phage Therapy Within a National Regulatory Framework: The Eliava Phage Therapy Center (EPTC) Model

Mariam Dadiani, Eliava Phage Therapy Center, Georgia

12h30 Lunch Break, Networking and Poster

Session 4 – Innovation Forum: Building the Future of Phage Therapy

Chairs: Frédéric Laurent, Martin J. Loessner & Evgenii Rubalskii



13h30

Chronic Respiratory Infections in the Inflamed Lung: Host-Pathogen Interactions and Opportunities for Phage Therapeutics

Paula Zamora, University of Kansas Medical Center, USA



14h00

Phage-Pseudomonas Interactions: Changes in Host Physiology and the Potential Impact on Phage Therapy

Piotr Golec, University of Warsaw, Poland



14h30

Advancing Personalized Phage Therapy in Hannover: Clinical Experience and Translational Progress

Evgenii Rubalskii, Hannover Medical School, Germany

15h00

Innovation Forum: From Scientific Concepts to Translational Impact

Adaptive Targeting: A High-Throughput Screening Strategy to Overcome Evolved Bacterial Resistance in Phage Therapy

Biswajit Biswas, US Navy, USA

Engineering Bacteriophages for Targeted Cancer Therapy

Henrique G. Ribeiro, LXbio Pharmaceuticals, Portugal

E. Coli Bacteriophages: A Natural Alternative for Managing Neonatal Diarrhea in Swine

Javier Quero, Exopol S.L., Spain

Phage-Derived Receptor-Binding Proteins for Precision Detection and Targeted Control of Carbapenem-Resistant *Klebsiella pneumoniae*

Silvio Santos, Universidade do Minho, Portugal

Virus-Like Particle and Other Protein Therapeutic Functionalization Using the Connectase Platform

Constantinos Patinios, Connectase, Lithuania

Biohybrids Composed of PRF and GELs with Antibacterial Phages for Controlled Therapeutic Delivery in Infected Wounds

Farzaneh Moghtader, TiPhage, Turkey



16h00 **Roundtable Discussion: Targeting Phage Therapy Beyond 2026: From Promise to Clinical Reality**
Chaired by Pilar Domingo-Calap, Institute of Integrative Systems Biology, Spain

With insights from: Benjamin K. Chan, Robert Atterbury, Frédéric Laurent, Barbara Brenner, and invited experts.

16h45 Concluding Note & Key Takeaways

16h55 Closing Remarks & Awards by Sandra Sevilla and Marvin Edeas
Targeting Phage Therapy 2026 Chairs

17h00 Drinks and Appetizer – Networking

17h15 **End of Targeting Phage Therapy 2026**

Thank you

KEYNOTE



Turning Evolution into Therapy: A New Strategy to Fight Antibiotic-Resistant Infections
Benjamin K. Chan, Yale University, USA



Advancing Phage Therapy for Chronic Infections: From Experimental Evidence to Clinical Use
Joana Azeredo, University of Minho, Portugal



Bacteriophages Redesigned: Engineering of Next-Generation Phage Therapeutics and Diagnostics
Martin J. Loessner, ETH Zürich, Switzerland



Shaping Phage Susceptibility Landscapes for Personalized Therapy
Katrine Whiteson, UC Irvine, USA (Online)



Phage for Sustainable and Scalable Infection Control in Aquaculture
Adelaide Almeida, Universidade de Aveiro, Portugal



Phage Therapy in Livestock Disease Models: Lessons for Animal and Human Health
Robert Atterbury, University of Nottingham, UK



Nasopharyngeal Phages: The Silent Players in Piglet Health
Oscar Mencia-Ares, Universidad de León, Spain



Roundtable Discussion: Targeting Phage Therapy Beyond 2026: From Promise to Clinical Reality
Pilar Domingo-Calap, Institute of Integrative Systems Biology, Spain



Personalized Bacteriophage Therapy in Germany and Beyond – A Consensus-Based Guideline
Annika Y. Classen, Cologne University Hospital, Germany



France launches its first public GMP Platform to produce large batches of Therapeutic Phages at affordable scale
Frédéric Laurent, Hospices Civils de Lyon, France



The Qualified Presumption of Safety (QPS) Qualification of Lytic Bacteriophages: Scientific Criteria and Regulatory Perspectives
Juan Evaristo Suárez, Universidad de Oviedo, Spain



From Bioreactor to Patient: Scalable Manufacturing and Delivery of Therapeutic Phages
Danish J. Malik, Loughborough University, UK



Chronic Respiratory Infections in the Inflamed Lung: Host-Pathogen Interactions and Opportunities for Phage Therapeutics
Paula Zamora, University of Kansas Medical Center, USA



Phage-Pseudomonas Interactions: Changes in Host Physiology and the Potential Impact on Phage Therapy
Piotr Golec, University of Warsaw, Poland



Personalized Phage Therapy at the Hannover Medical School: Barriers, Challenges, and Next Steps
Evgenii Rubalskii, Medizinische Hochschule Hannover, Germany

**PHAGE
THERAPY 2026**

TARGETING MICROBIOTA

SEPT. 24 > 25 2026 > TOKYO



PROGRAM